Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.
Silas Inman
Articles by Silas Inman
The results of vorasidenib signal potential for the agent to become the first targeted therapy in low-grade glioma.
MD Anderson Cancer Center's Hans C. Lee, MD has presented promising results from the phase 2 LINKER-MM1 study at ASCO.
The first study of a dual bispecific combination in relapsed or refractory multiple myeloma encourages the investigators.
News from KEYNOTE-671 in early-stage non–small cell lung cancer provides more evidence to support the FDA approval application for perioperative pembrolizumab.
The PARP inhibitor rucaparib bested physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer in the phase 3 TRITON3 study.
Sacituzumab govitecan-hziy demonstrated a promising objective response rate in platinum-ineligible patients with metastatic urothelial cancer after progression on an immune checkpoint inhibitor.
Findings from the phase 2 HCRN GU 16-257 trial may help advance a more personalized approach to the management of muscle-invasive bladder cancer.
Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma.
In the phase 3 TRANSFORM study, lisocabtagene maraleucel bested standard of care as treatment of patients with high-risk relapsed/refractory large B-cell lymphoma.
Phase 3 TRIANGLE results show the efficacy of ibrutinib induction and ibrutinib maintenance in patients with mantle cell lymphoma.
Phase 1/2 BRUIN study results show high response rates in patients with Waldenström macroglobulinemia who were treated with pirtobrutinib.
Positive results were reported on the phase 2 MagnetisMM-3 study at the ASH Annual Meeting 2022.
Significant improvements in progression-free survival were seen with sotorasib compared with docetaxel in patients with KRAS G12C–mutated non–small cell lung cancer.
Even after additional follow-up, the CLEAR trial showed a benefit for the combination of lenvatinib and pembrolizumab over sunitinib in patients with advanced clear cell renal cell carcinoma.
Positive signals from a blood-based multi-cancer early detection test led to cancer diagnoses after the test indicated potential cancers in 1.4% of individuals from an otherwise healthy cohort of participants in the the prospective PATHFINDER study.
The oncolytic virus T-VEC showed consistent improvements at 5 years for patients with stage IIIB to IVM1a melanoma.
A novel tumor-infiltrating lymphocyte therapy showed a 50% reduction in the risk of death for patients with stage IIIC/IV unresectable, treatment-refractory melanoma.
Findings presented at ESMO 2022 show the survival benefits of camrelizumab plus rivoceranib in patients with unresectable HCC.
A case report for zenocutuzumab supports emerging evidence that NRG1 fusions are targetable driver mutations in metastatic breast cancer.
Rivoceranib showed promising responses in regard to objective response rate and disease control rate when used in patients with recurrent or metastatic adenoid cystic carcinoma.
According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.
At the 2022 ASCO Annual meeting, trastuzumab dreuxtecan was found to be a superior standard of care therapy for patients with hER2-low, hormone-positive metastatic breast cancer.
Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.
A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer
According to Michael Dickinson, MBBS, glofitamab is a highly active drug. The agent showed durable response in patients with heavily pretreated large B-cell lymphoma.
Chemotherapy may be avoidable for patients with stage II colon cancer, and circulating tumor DNA has demonstrated the ability to detect which patients, according to phase 2 study results.
Results from the phase 3 EVEREST trial presented during the 2022 ASCO Annual Meeting reveal the relapse-free survival advantage of using adjuvant everolimus over placebo in patient with high-risk renal cell carcinoma.
Treatment with sugemalimab shown to be well-tolerated and have a consistent safety profile to other studies, according to results of the GEMSTONE-201 trial.
According to real-world research, eribulin may be an effective treatment for patients with metastatic breast cancer who were previously treated with atezolizumab or sacituzumab govitecan.